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In Brief
Numerous assembly and chaperone
proteins are involved in the biogenesis of
cytochrome c oxidase (Complex IV),
including COX2, which houses its redox-
active copper center. Pacheu-Grau et al.
show that cytochrome c oxidase
assembly factor 6 (COA6) is part of the
COX2 copper relay system involving the
copper metallochaperone SCO2.
Mutations preventing SCO2/COA6
interactions underlie patient
mitochondrial cardiomyopathies.
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Three mitochondria-encoded subunits form the cat-
alytic core of cytochrome c oxidase, the terminal
enzyme of the respiratory chain. COX1 and COX2
contain heme and copper redox centers, which are
integrated during assembly of the enzyme. Defects
in this process lead to an enzyme deficiency and
manifest as mitochondrial disorders in humans.
Here we demonstrate that COA6 is specifically
required for COX2 biogenesis. Absence of COA6
leads to fast turnover of newly synthesized COX2
and a concomitant reduction in cytochrome c oxi-
dase levels. COA6 interacts transiently with the
copper-containing catalytic domain of newly syn-
thesized COX2. Interestingly, similar to the copper
metallochaperone SCO2, loss of COA6 causes car-
diomyopathy in humans. We show that COA6 and
SCO2 interact and that corresponding pathogenic
mutations in each protein affect complex formation.
Our analyses define COA6 as a constituent of the
mitochondrial copper relay system, linking defects
in COX2metallation to cardiac cytochrome c oxidase
deficiency.
INTRODUCTION
The mitochondrial oxidative phosphorylation system generates
the bulk of cellular ATP, fueling the energetic demands of most
eukaryotes. Five multi-subunit protein complexes in the mito-
chondrial inner membrane, termed complexes I to V, comprise
the oxidative phosphorylation system. These complexes are ge-
netic hybrids. Thirteen core subunits of complexes I, III, IV, and V
are encoded in the mitochondrial genome, while the remaining
subunits are nuclear-encoded and imported into mitochondria
(Mick et al., 2011; Soto et al., 2012). Hence, enzyme complexes
assemble from subunits that reach the inner membrane via
different transport routes. Moreover, redox-active cofactors
have to be inserted during maturation of respiratory chain com-Cplexes. In the case of cytochrome c oxidase (complex IV), which
oxidizes cytochrome c and transfers electrons to molecular ox-
ygen, the mitochondria-encoded COX1 and COX2 house the
redox-active heme and copper centers. While COX1 contains
two heme moieties (a and a3) and the CuB site, the CuA site is
positioned in the intermembrane space domain of COX2. A
plethora of factors participate in the process of protein assembly
and cofactor insertion, and perturbation of the assembly process
causes a cytochrome c oxidase deficiency and severe disorders
in humans.
Cytochrome c oxidase assembly initiates with the synthesis of
COX1, which associates with assembly factors in the inner mito-
chondrial membrane, forming the MITRAC intermediate in hu-
mans. This association stabilizes COX1 and feedback-regulates
the translation of COX1 mRNA. Insertion of heme, a process in
which the SURF1 protein is implicated, is thought to occur
once the first nuclear-encoded subunits have engaged with
COX1. COX2 also spans the inner mitochondrial membrane,
and contains soluble N- and C-terminal tails that protrude into
the intermembrane space. OXA1mediates export of theN-termi-
nal tail of COX2 (Hell et al., 1997, 1998), while COX18 is required
for export of its C terminus (Fiumera et al., 2007; Saracco and
Fox, 2002). Delivery of copper to the CuA site contained within
the C-terminal tail of COX2 depends on a relay of metallochaper-
ones in the intermembrane space. COX17 is crucial for copper
delivery to both COX1 and COX2. The transfer of copper from
COX17 to COX1 is facilitated by COX11 (Herrmann and Funes,
2005). In the case of copper transfer from COX17 to the CuA
site, two related proteins, SCO1 and SCO2, are involved (Herr-
mann and Funes, 2005). SCO1 participates in delivering copper
to COX2 (Krummeck and Ro¨del, 1990; Rigby et al., 2008;
Schulze and Ro¨del, 1988), whereas the function of SCO2 has re-
mained elusive. In yeast, Sco2 is dispensable for cytochrome c
oxidase biogenesis but is nonetheless able to partially comple-
ment Sco1 deficiency, indicating that Sco1 and Sco2 have over-
lapping functions (Banci et al., 2011). In contrast to yeast, human
mitochondria possess two Sco1 homologs, termed SCO1 and
SCO2, both of which are essential and have non-overlapping
functions in the biogenesis of the CuA site (Horng et al., 2005).
SCO2 has been proposed to act upstream of SCO1, hinting at
a sequential copper delivery process for metallation of COX2
(Leary et al., 2004, 2009). After COX2 metallation, the COX1ell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc. 823
and COX2 assembly lines merge and biogenesis of the enzyme
complex continues by addition of COX3 and the other imported
subunits.
Defects in heme a synthesis or delivery, as well as in copper
chaperone function, have been linked to severe human disorders
with cytochrome c oxidase deficiency. Patients with SCO1 mu-
tations display cytochrome c oxidase deficiency, leading to fatal
encephalopathy, hypertrophic cardiomyophathy, neonatal hep-
atopathy, and ketoacidotic comas (Stiburek et al., 2009; Valnot
et al., 2000; Leary et al., 2013). In contrast, mutations in SCO2
are associated with neonatal encephalocardiomyopathy (Papa-
dopoulou et al., 1999) or hypertrophic cardiomyopathy (Jaksch
et al., 2000). Surprisingly, these distinct clinical phenotypes are
not due to tissue-specific expression of SCO1 and SCO2, since
both are ubiquitously expressed (Papadopoulou et al., 1999).
One explanation for this could be that other factors involved in
COX2 maturation contribute to the tissue selective phenotype.
Exome sequencing approaches have now significantly ex-
tended the number of known pathogenic mutations affecting
complexes of the oxidative phosphorylation system, expanding
the set of factors putatively involved in the biogenesis of its
enzyme complexes. One example for this is COA6. A recent
sequencing study on infants with mitochondrial disorders identi-
fied a mutation in COA6 (C1orf31). The patient presented with
hypertrophic cardiomyopathy, severe complex IV deficiency,
and a mild reduction in complex I activity in heart tissue (Calvo
et al., 2012). A secondCOA6 patient, also with fatal hypertrophic
cardiomyopathy, was recently reported (Baertling et al., 2015).
The yeast homolog of COA6 had been identified previously in a
proteomic study as a mitochondrial intermembrane space pro-
tein (Ghosh et al., 2014; Vo¨gtle et al., 2012). coa6D cells display
reduced levels of cytochrome c oxidase (Ghosh et al., 2014;
Vo¨gtle et al., 2012). While a partial suppression of mutant pheno-
types in the presence of high copper concentrations has been
reported, the function of COA6 and why its loss leads to cardio-
myopathy remains unknown (Baertling et al., 2015; Calvo et al.,
2012; Ghosh et al., 2014).
Here, we define the molecular function of COA6. We demon-
strate that COA6 interacts with newly synthesized COX2 and
that this interaction is conserved from yeast to man. In yeast
mitochondria, Coa6 interacts with Sco1 and Sco2 preferentially
in the absence of Cox2. In human mitochondria, COA6 selec-
tively interacts with SCO2 in a COX2-dependent manner. A
loss of COA6 leads to fast turnover of COX2, explaining the
reduction in cytochrome c oxidase levels. Interestingly, patho-
genic amino acid substitutions in both SCO2 and COA6 destabi-
lize complex formation, thus linking the SCO2/COA6 interaction
with the observed cardiac defect. We conclude that COA6 is a
new constituent in the COX2 copper relay system, promoting
SCO2 function during the metallation process.
RESULTS
COA6 Is Required for Cytochrome c Oxidase Biogenesis
In Saccharomyces cerevisiae, Coa6 is an intermembrane space
protein that is released frommitochondria upon outer membrane
opening and that is characterized by the presence of a
Cx9CxnCx10C motif (Ghosh et al., 2014; Vo¨gtle et al., 2012).
Interestingly, COA6 is highly conserved from yeast to metazoa824 Cell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc.(Figure S1). To assess the function of human COA6 (C1orf31)
and understand how its malfunction leads to cardiomyopathy,
we determined the localization of human COA6 by transfecting
U2OS cells with COA6 containing a C-terminal FLAG-tag. Immu-
nofluorescence microscopy demonstrated colocalization of
COA6FLAG with mitotracker labeling (Figure 1A). Next, we gener-
ated a stable HEK293T cell line expressing COA6with a C-termi-
nal FLAG tag. Carbonate extraction and detergent treatment
released COA6 into the soluble fraction, while the integral mem-
brane proteins TIM23 and MITRAC12 were only solubilized by
detergent treatment (Figure 1B). Moreover, COA6FLAG was pre-
sent in isolated mitochondria where it only became accessible
to externally added protease under conditions of outer mem-
brane disruption, such as hypo-osmotic treatment (mitoplasts)
or sonication (Figure 1C). Since defects in COA6 function cause
cardiomyopathy in humans, we assessed expression levels of
COA6 isoform 1 in different mouse tissues by qPCR. COA6
displayed increased expression in tissues with a high energy
demand, such as heart, liver, and kidney (Figure 1D). Hence,
no tissue-specific expression of COA6 was apparent, but rather
an expression pattern resembling typical mitochondrial proteins
(Vukotic et al., 2012; Yao and Shoubridge, 1999).
To assess COA6 function, we established a cellular model in
which we downregulated the amount of COA6 by siRNA treat-
ment. Upon treatment of HEK293T cells with siRNA targeted
against COA6, doubling of cells was significantly affected after
3 days and exacerbated after that (Figure 1E). To reduce non-
specific effects due to the loss of COA6, we harvested cells after
4 days of treatment for further analyses.
Since coa6D yeast cells display reduced levels of cytochrome
c oxidase similar to patients carrying mutations in COA6, we
assessed respiratory chain function upon COA6 knock-down.
We analyzed the oxygen consumption rate of COA6 knock-
down cells by real-time respirometry and observed drastically
decreased oxygen consumption at basal and maximal capacity
compared to control cells (Figure 1F). This phenotype was ex-
plained by significantly decreased cytochrome c oxidase activity
and reduced overall levels of the enzyme complex (Figure 1G).
Loss of activity and reduced cytochrome c oxidase content
correlated with each other, indicating that enzyme activity
directly reflects complex abundance (Figure 1H). Since defects
in complex I activity had been described for one COA6 patient
but were not apparent in a second pedigree (Baertling et al.,
2015; Calvo et al., 2012), we also measured the enzymatic activ-
ity and the total amount of complex I. Cells with reduced COA6
levels displayed a significant decrease in complex I activity
and content (Figure 1I). Accordingly, a lack of COA6 caused
complex I and complex IV defects in HEK293T cells.
COA6 Interacts with Newly Synthesized COX2 in Human
and Yeast Mitochondria
Our results demonstrate that human COA6, similar to its yeast
homolog, is required for cytochrome c oxidase function and
biogenesis. However, how COA6 contributes to cytochrome c
oxidase assembly remained to be assessed.
Assembly of cytochrome c oxidase is initiated with the synthe-
sis of COX1, which engages with amultitude of assembly factors
in the inner mitochondrial membrane to form an early assembly
intermediate called MITRAC (Mick et al., 2012). To address if
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Figure 1. COA6 Is Required for Cytochrome c Oxidase Biogenesis
(A) Immunofluorescence analysis of U2OS cells after transient transfection with COA6FLAG using anti-FLAG antibodies and Mitotracker.
(B) Mitochondria containing COA6FLAG were subjected to carbonate extraction or detergent lysis, followed by differential centrifugation; pellet, P; supernatant, S;
total, T. Samples were analyzed by SDS-PAGE and western blotting.
(C) Submitochondrial localization analysis using COA6FLAG mitochondria. Mito, mitochondria; MP, mitoplasts; Sonic., sonication; PK, proteinase K. Samples
were analyzed by SDS-PAGE and western blotting.
(D) mRNA levels of COA6 in indicated mouse tissue samples. Right ventricle, RV; left ventricle, LV.
(E) Cell count after treatment of cells with siRNA directed against COA6 compared to control cells.
(F) Real-time respirometry of COA6 knock-down and control cells; oxygen consumption rates, OCR.
(G) Cytochrome c oxidase activity and content in COA6 knock-down and control cells (SEM, n = 3) was determined by spectrophotometric measurement and
affinity capture of the complex, respectively, as described in Experimental Procedures.
(H) Regression plot of activity values versus cytochrome c oxidase content (from [G]) (r = 0.92).
(I) Complex I activity and content in COA6 knock-down and control cells (SEM, n = 4). Enzymatic activity was determined by spectrophotometry, and amount of
complexes was determined by ELISA.
See also Figure S1.COA6 was part of MITRAC in human mitochondria, we per-
formed immunoprecipitation of MITRAC12 (Clemente et al.,
2013; Mick et al., 2012) from wild-type and COA6FLAG mitochon-
dria. MITRAC12 coimmunoprecipitated known components of
the MITRAC complex, such as COX1 and COX4-1. However,
COA6 did not copurify with MITRAC12 (Figure 2A), demon-
strating that COA6 does not participate in early steps of COX1
assembly.
To analyze if COA6 interacts with other complexes contain-
ing newly synthesized mitochondria-encoded proteins, we ra-
diolabelled mitochondrial translation products in COA6FLAG orCMITRAC12FLAG cells and performed immunoisolation. As ex-
pected, COX1, and to a lesser extent other mitochondria-en-
coded subunits, copurified with MITRAC12 (Mick et al., 2012).
Interestingly, newly synthesized COX2 was isolated together
with COA6 (Figures 2B and S2A).
COX2 is part of the catalytic core of cytochrome c oxidase and
is conserved among species (Soto et al., 2012). To assess if the
COA6/COX2 interaction is conserved between human and yeast
mitochondria, we labeled mitochondrial translation products
and performed immunoprecipitations using antiserum directed
against Coa6. Indeed, newly synthesized Cox2 was specificallyell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc. 825
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Figure 2. COA6 Interacts with Newly Synthesized COX2
(A) Anti-MITRAC12 immunoprecipitation from control or COA6FLAG-containing mitochondria. Total, 5%; eluate, 100%. Samples were subjected to SDS-PAGE
and western blotting.
(B) Anti-FLAG immunoprecipitation from control, COA6FLAG-, or MITRAC12FLAG-containing cells after radiolabeling of mitochondrial translation products. Total,
5%; eluate, 100%. Samples were analyzed by SDS-PAGE and digital autoradiography or western blotting.
(C) Immunoprecipitation from digitonin-solubilized mitochondria after in organello radiolabeling (20 min) of mitochondrial translation products using anti-Coa6 or
control antibodies. Total, 4%; eluate, 100%. Samples were analyzed by SDS-PAGE and digital autoradiography. Fold enrichment over control sample: Cox1, 0.7;
Cox2, 5.7; Cox3, 1.4.
(D) Isolated wild-type (WT) and coa6D mitochondria were analyzed by western blotting.
(E) Enzymatic activity of complex III or complex IV in wild-type and coa6D mitochondria (SEM, n = 3). See also Figure S2.copurified with Coa6, indicating the conservation of this interac-
tion and potentially COA6 function (Figure 2C). Because Cox2
was not significantly enriched in Coa6 immunoprecipitates by
western blotting (Figure S2B), we conclude that the interaction
between Cox2 and Coa6 is transient and only occurs early after
Cox2 synthesis.
To address if absence of Coa6 in yeast mitochondria has a
specific effect on Cox2, we analyzed steady-state protein levels
in wild-type and coa6D mitochondria. The levels of Cox2 and
other structural subunits of cytochrome c oxidase, such as
Cox1 and Cox3, were reduced in coa6D mitochondria (Fig-
ure 2D). The levels of nuclear-encoded COX subunits such as
Cox5 and Cox6 were also reduced, albeit to a lesser extent. In
contrast, the protein levels of assembly factors such as Coa1,
Coa3, Shy1, and the translational regulator of Cox1, Mss51,
were not affected (Figure 2D). In agreement with the observed826 Cell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc.reduction of cytochrome c oxidase on blue native PAGE (Ghosh
et al., 2014; Vo¨gtle et al., 2012), isolated coa6D mitochondria
showed selectively decreased cytochrome c oxidase activity
(Figure 2E).
COA6 Interacts with the Copper Insertion Machinery
and Is Required for COX2 Stability
To address if Coa6 affects translation of the COX2 mRNA, we
pulse-labeled mitochondrial translation products in yeast cells
under conditions of inhibited cytosolic translation. Cox2 was
barely detectable in coa6D cells (Figure 3A). This observation
could be interpreted as an indication for reduced translation of
Cox2 in cells lacking Coa6. To directly assess this possibility,
we pulse-labeledmitochondrial translation products over a short
time interval. We observed that less Cox2 was detectable with
longer pulses in yeast cells lacking Coa6 (Figure 3B). Since a
direct effect of Coa6 on mitochondrial ribosomes is unlikely, as
Coa6 localizes to the intermembrane space, we assessed if
newly synthesized Cox2 is destabilized in the absence of
Coa6. We pulse-labeled mitochondrial translation products in
wild-type and coa6D cells and monitored the fate of mitochon-
drial translation products over a brief 5 min chase period with
unlabeled methionine. While the stability of Cox3 was largely
unaffected (Figure S3A), newly synthesized Cox2 was rapidly
turned over in the deletion strain, having a half-life of approxi-
mately 3 min (Figure 3C). It is interesting to note that Cox2 was
also unstable after labeling translation products in isolated mito-
chondria. However, the kinetics of Cox2 turnover was slower
than in intact cells, suggesting that mitochondrial dynamics or
cellular organization may contribute to the quality control pro-
cess in vivo (data not shown). In conclusion, absence of Coa6
in yeast cells leads to decreased amounts of Cox2 through
increased protein turnover, eventually leading to a loss of cyto-
chrome c oxidase.
Coa6 and its human homolog, COA6, are localized in the mito-
chondrial intermembrane space (IMS). Cox2 possesses two
transmembrane spans, exposing a short N-terminal and a cata-
lytic C-terminal tail into the intermembrane space (Figure 3D). In
yeast, the N terminus of Cox2 undergoes proteolytic processing
by the intermembrane space processing peptidase (IMP) (Nun-
nari et al., 1993). Cox18 is required for export of the Cox2 C ter-
minus into the IMS (Saracco and Fox, 2002). We speculated that
Coa6 interacts with either the soluble N-terminal or C-terminal
domain of Cox2. Hence, we assessed the interaction of newly
synthesized Cox2 with Coa6 in cox18D and imp1D mitochon-
dria. In imp1D mitochondria, the interaction of Cox2 with Coa6
was similar to wild-type, indicating that N-terminal processing
is not required for Coa6 binding. In contrast, no interaction be-
tween Cox2 and Coa6 was found in cox18D mitochondria (Fig-
ure 3E). In cells lacking Cox18, the N terminus of Cox2 is inserted
into the inner membrane and processed, and Cox2 is therefore
resistant to protease degradation after swelling (Fiumera et al.,
2007; Fiumera et al., 2009) and to carbonate extraction (Fig-
ure S3B). Thus, we conclude that Coa6 interacts with Cox2 via
its IMS-exposed C-terminal tail.
Cox1 is the central platform for assembly of cytochrome c ox-
idase. A regulatory feedback mechanism couples COX1 transla-
tion to its assembly, ensuring that Cox1 is synthesized at an
appropriate rate (Fontanesi et al., 2008; Kim et al., 2012; Mick
et al., 2011; Ott and Herrmann, 2010). To assess if the interaction
between Coa6 and Cox2 is affected in the absence of Cox1, we
immunoprecipitated Coa6 after labeling ofmitochondrial transla-
tion products in isolated mitochondria lacking Cox1. Similar
amounts of Cox2 coimmunoprecipitated in cox1 and wild-
type mitochondria (Figure 3F). This finding indicates that the
interaction between Coa6 and Cox2 occurs before incorporation
of Cox2 into the Cox1 assembly line.
The C-terminal domain of Cox2 forms a ten-stranded b-barrel
containing the binuclear CuA center (Tsukihara et al., 1996). Tak-
ing this, and the presence of a Cx9CxnCx10C motif in Coa6, into
account, we investigated the Cox2/Coa6 interaction in the
context of proteins involved in copper delivery to Cox2. The
delivery of copper to the CuA site involves the metallochaperone
Sco1. A related protein in yeast, Sco2, is dispensable for
cytochrome c oxidase assembly but can compensate for lossCof Sco1 upon its overexpression. Serendipitously, we detected
Sco1 in Coa6 immunoprecipitations. Interestingly, Sco1 or
Sco2 were not significantly recovered when Coa6 was precipi-
tated from wild-type mitochondria, but only in cox2 mutant
mitochondria (Figure 3F). Based on this finding, we performed
immunoprecipitation experiments using mitochondria from
several mutant strains: pet111D, defective in Cox2 translation;
rho0, lacking functional mitochondrial DNA; and cox18D. Only
low amounts of Sco1 and Sco2 copurified with Coa6 in wild-
type mitochondria. However, significantly increased copurifica-
tion of Sco1 and Sco2 was observed in mitochondria lacking
Cox2 (rho0, pet111D). Moreover, increased Sco1 and Sco2 cop-
urification was apparent in cox18Dmitochondria (Figure 3G and
Figure S3C). The observed increased association between Coa6
and Sco1/Sco2 in the absence of Cox2 indicates that Coa6 plays
a role in copper insertion/delivery. Hence, we analyzed copper
binding of Coa6. We expressed and purified GST-Coa6, GST-
Sco1, and GST-Sco2 fusion proteins from E. coli cells. Copper
content was assessed by atomic absorption spectrophotom-
etry.While GST alone did not contain significant amounts of cop-
per, GST-Coa6, GST-Sco1, and GST-Sco2 contained similar
amounts of copper in this assay (Figure S3D). These data sug-
gest that Coa6 is able to bind copper with an affinity similar to
the Sco proteins when expressed in E. coli.
To assess if the interaction between Coa6 and Cox2 depends
on the mitochondrial copper-relay system, we performed Coa6
immunoprecipitation after labeling of mitochondrial translation
products in mitochondria frommutants lacking proteins involved
in mitochondrial copper homeostasis. Cox17 is a copper-bind-
ing metallochaperone, containing a CCXC motif, and transfers
copper to Sco1 and Cox11, which are responsible for copper
insertion into the CuA and CuB sites, respectively (Carr et al.,
2002; Glerum et al., 1996). Sco2 and Sco1 display sequence
similarity and have overlapping but not identical functions (Banci
et al., 2011; Glerum et al., 1996; Leary, 2010). Cox19 and Cox23
are putative copper chaperones localized to the intermembrane
space. However, their function is still not well defined (Barros
et al., 2004; Rigby et al., 2007). The normalized amount of newly
synthesized Cox2 that coimmunoprecipitated with Coa6 was
considerably increased in cox11D, cox17D, cox19D, cox23D,
and sco1D mitochondria, compared to wild-type (Figures 3H
and S3E). In contrast, deletion of SCO2 resulted in significantly
decreased Cox2 copurification (Figures 3H and S3E). Thus, in
the absence of copper chaperones involved in copper transfer
to Cox2, Coa6 accumulated in a Cox2-associated state. In
contrast, a lack of Sco2 led to an apparent loss of the Coa6/
Cox2 interaction (Figures 3H and S3E). Accordingly, in yeast,
Coa6 interacted with Cox2 in a copper-chaperone-dependent
manner. As the interaction between Sco1/2 and Coa6 was
increased in the absence of Cox2, we conclude that Coa6 accu-
mulates in a complex with themetallochaperones in the absence
of its substrate.
Human SCO2 and COA6 Form a Complex
To address if the interaction between COA6 and SCO proteins is
conserved in human cells and depends on COX2, we performed
immunoisolation of COA6FLAG from mitochondria isolated from
non-treated cells or cells treated with specific inhibitors of
cytosolic (emetine) or mitochondrial (thiamphenicol) translationell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc. 827
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Figure 3. Coa6 Interacts with Copper Insertion Machinery and Affects Stability of Newly Synthesized Cox2
(A) In vivo labeling of mitochondrial translation products in wild-type and coa6D cells. Samples were pulsed for 10 min and analyzed by SDS-PAGE and digital
autoradiography.
(B) Mitochondrial translation products were labeled in vivo for different pulse times. Quantification of newly synthesized Cox2 in wild-type and coa6D cells,
normalized to Cob (SEM, n = 4).
(C) Mitochondrial translation products were labeled in vivo for 10 min and samples taken during the chase. Quantification of newly synthesized Cox2 in wild-type
and coa6D cells, normalized to Cob (SEM, n = 3).
(D) Structure of COX2 in bovine cytochrome c oxidase (PDB 3ASN). IMM, inner mitochondrial membrane. IMS, intermembrane space.
(legend continued on next page)
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Figure 4. COA6 Interacts Specifically with
SCO2
(A) Anti-FLAG immunoprecipitation from control
and COA6FLAG mitochondria. Mitochondria were
isolated from non-treated cells or from cells
treated with emetine or thiamphenicol. Total, 5%;
eluate, 100%. Samples were subjected to SDS-
PAGE and analyzed by western blotting.
(B) BN-PAGE analyses from control and COA6FLAG
mitochondria. Samples were analyzed by western
blotting.
(C) After radiolabeling of mitochondrial translation
products, COA6FLAGmitochondria were subjected
to anti-FLAG immunoprecipitation and eluates
subsequently analyzed by 1D BN- and 2D SDS-
PAGE. Samples were analyzed by digital autora-
diography or western blotting.
(D) After transient transfection with wild-type or
mutant COA6FLAG, mitochondrial translation prod-
ucts were radiolabeled and anti-FLAG immuno-
precipitation performed. Total, 5%; eluate, 100%.
Samples were analyzed by SDS-PAGE digital
autoradiography or western blotting.
(E) Immunofluorescence analysis of U2OS cells
after transient transfection with COA6FLAG and
COA6FLAG-W59C expressing plasmids using anti-
FLAG antibodies and Mitotracker (Bar = 10 mm).
(F) Submitochondrial localization analysis using
mitochondria derived from COA6FLAG expressing
cells and cells transfected with COA6FLAG-W59C.
Mito, mitochondria; MP, mitoplasts; Sonic., soni-
cation; PK, proteinase K. Samples were analyzed
by SDS-PAGE and western blotting.(Chomyn, 1996; Mick et al., 2012). Human mitochondria have
two homologs of yeast Sco1, termed SCO1 and SCO2 (Soto
et al., 2012). Interestingly, COA6FLAG specifically coisolated
with SCO2, but not with SCO1. Moreover, treatment with
thiamphenicol strongly affected the COA6/SCO2 interaction
(Figure 4A). Accordingly, also in human mitochondria, COA6
interacted with metallochaperones of the SCO family. However,
COA6 displayed SCO2 specificity and did not interact sig-
nificantly with SCO1. Moreover, in human cells, COX2 is(E and F) Immunoprecipitation of Coa6 from digitonin-solubilized mitochondria isolated from indicated strai
translation products. Total, 4%; eluate, 100%. Samples were analyzed by SDS-PAGE and digital autoradiog
(G) Immunoprecipitation of Coa6 from digitonin-solubilized wild type and mutant mitochondria. Samples we
(H) Quantification of radiolabeled Cox2 co-immunoprecipitated with Coa6. Samples were normalized to the
Figure S3.
Cell Metabolism 21, 823–required for the interaction between
COA6 and SCO2. In BN-PAGE analyses,
COA6 formed a single complex of
approximately 70 kDa at steady-state
(Figure 4B). We radiolabelled mitochon-
drial translation products and isolated
the COA6FLAG-containing complex under
native conditions. The purified complex
was first separated on BN-PAGE and
then subjected to a 2D separation on
SDS-PAGE. Radiolabelled COX2 copuri-
fied with COA6FLAG and comigratedtogether with COA6 and SCO2, suggesting that these proteins
form a ternary complex (Figure 4C).
Patients with mutations in SCO1 and SCO2 present with early-
onset mitochondrial disease in which affected tissues exhibit a
cytochrome c oxidase deficiency and a profound reduction of
their total copper content. Interestingly, mutations in SCO1
have been reported to cause fatal encephalopathy, hypertrophic
cardiomyophathy, neonatal hepatopathy, and ketoacidotic co-
mas (Stiburek et al., 2009; Valnot et al., 2000; Leary et al.,ns after in organello radiolabeling of mitochondrial
raphy ([E] and [F]) or western blotting (F).
re analyzed by SDS-PAGE and western blotting.
amount present in the total (SEM, n = 3). See also
833, June 2, 2015 ª2015 Elsevier Inc. 829
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Figure 5. Mutations in SCO2 and COA6 Affect Protein Association
(A) After transient transfection with wild-type or mutant SCO2HA, cells
expressing COA6FLAG were solubilized in digitonin and analyzed by western
blotting. Total, 5%; eluate, 100%.
(B) Quantification of the amount of SCO2HA coimmunoprecipitated with COA6,
normalized to the total amount of SCO2 and of COA6 immunoprecipitated in
each sample (SEM, n = 3).
(C) After radiolabeling of mitochondrial translation products, SCO2FLAG mito-
chondria were subjected to anti-FLAG immunoprecipitation and eluates sub-
sequently analyzed by SDS-PAGE and digital autoradiography.
(D) Following siRNA treatment and radiolabelling of mitochondrial translation
products, SCO2FLAG was immunoprecipitated and eluates analyzed by SDS-
PAGE, western blotting, and digital autoradiography. The amount of newly
synthesized COX2 was quantified and standardized to the precipitated
amount of SCO2 (range, n = 2).2013), whereas mutations in SCO2 are primarily associated with
neonatal hypertrophic cardiomyophathy (Jaksch et al., 2000).
Hence, SCO2 defects appear to cause a clinical phenotype
resembling that seen in COA6 patients. In the case of COA6,
two alleles have been identified in patients that encode COA6
with amino acid substitutions within, or in proximity to, the
Cx9CxnCx10C motif (Baertling et al., 2015; Ghosh et al., 2014).
We therefore expressed a COA6FLAG variant harboring the path-
ogenic W59C substitution and analyzed whether it affected
COA6 interactions with COX2 and SCO2. After radiolabeling of
mitochondrial translation products, COX2 coisolated with wild-
type COA6 but not with the COA6-W59C variant (Figure 4D).
Moreover, western blot analyses revealed that the mutant
COA6 was no longer able to interact with SCO2 (Figure 4D).830 Cell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc.Coa6 in yeast was reported to be imported via the MIA pathway,
in agreement with the presence of a Cx9CxnCx10C motif (Vo¨gtle
et al., 2012). The W59C substitution introduces an additional
cysteine residue into this motif that may affect the mitochondrial
localization of the mutant protein. To address this possibility, we
expressed COA6FLAG with a W59C substitution in U2OS cells
and assessed mitochondrial localization by fluorescence micro-
scopy. Both COA6FLAG and COA6FLAG-W59C localized to mito-
chondria (Figure 4E). To further analyze the submitochondrial
localization of the W59C variant, we performed protease acces-
sibility assays after swelling of mitochondria expressing wild-
type COA6 or the mutant protein. While wild-type COA6 was
sensitive to protease treatment in mitoplasts, the W59C variant
was resistant, indicating protection by the inner mitochondrial
membrane. These analyses point to the mislocalization of the
COA6-W59C variant to the mitochondrial matrix (Figure 4F).
Accordingly, the molecular basis for a loss of COA6-W59C func-
tion is an intramitochondrial transport defect caused by a single
amino acid substitution.
Pathogenic Mutations in SCO2 Affect Its Interaction
with COA6
Since expression of the pathogenic W59C allele of COA6 re-
sulted inmislocalization of the protein, we analyzed if pathogenic
mutations in SCO2 affected its ability to associate with COA6.
We generated HA-tagged variants of SCO2 (SCO2HA-R114H,
SCO2HA-R171W), mimicking mutations found in SCO2 patients.
After transfection into COA6FLAG-expressing cells, we assessed
SCO2/COA6 association. While the R171W substitution
rendered SCO2 unstable, SCO2HA-R114H remained stable in
mitochondria (Figure 5A, lanes 1–3). The presence of the
R114H substitution reduced the level of SCO2 copurifying with
COA6 by 80% (Figures 5A and 5B). Thus, expression of a path-
ogenic allele of SCO2 significantly affected its interaction with
COA6.
Newly synthesized COX2 can be specifically coisolated
together with SCO2 (Figure 5C). To address if a loss of COA6
affected this association, we carried out SCO2FLAG immunoiso-
lations after COA6 knock-down or treatment of cells with a non-
targeting control. Upon reduction of COA6, the amount of newly
synthesized COX2, which coisolated together with SCO2FLAG,
was significantly decreased (Figure 5D), indicating that COA6
is required for SCO2 to bind to COX2 or to stabilize this
association.
We conclude that COA6 and SCO2 interact with each other
under physiological conditions to cooperate in COX2maturation.
A loss of COA6 interaction with SCO2 and/or COX2 causes cy-
tochrome c oxidase deficiency (Figure 6). Moreover, the SCO2/
COX2 interaction depends on COA6. Since defects in COA6
and SCO2 function cause cardiomyopathy in humans, we sug-
gest that the pathology of the patients is linked to tissue-specific
requirements during copper incorporation into COX2.
DISCUSSION
Cytochrome c oxidase deficiency leads to a variety of severe
human disorders (Ghezzi and Zeviani, 2012; Shoubridge,
2001). Here we find that cells lacking COA6 display a significant
reduction in cytochrome c oxidase activity and total content.
Figure 6. COA6 Cooperates with SCO2 in COX2 Metallation and As-
sembly of Cytochrome c Oxidase
COA6 and SCO2 cooperate in CuA site formation of COX2. Mutations in COA6
or SCO2 affecting their interaction cause defects in thematuration of the COX2
CuA site. Consequently, assembly of the cytochrome c oxidase is disturbed.Moreover, SCO2 and COA6, which have been causally linked to
severe cardiac disorders, physically interact. Our analyses indi-
cate that a loss of complex formation contributes to the molec-
ular pathology of the disorders, since pathogenic variants of
SCO2 and COA6 lose their ability to interact with one another.
In the case of the W59C variant of COA6, we find that the mutant
protein is misrouted into the mitochondrial matrix, instead of be-
ing physiologically directed into the intermembrane space by the
MIA pathway. Hence, in patient mitochondria, mutant COA6 is
no longer available to its interaction partners. It is tempting to
speculate that the introduction of an additional cysteine residue
affects recognition of COA6 by the MIA transport machinery.
However, themechanism by which the pathogenicW59C variant
is directed into thematrix will require detailed analyses on cryptic
targeting signals within the COA6 protein.
SCO2 is a core constituent of the mitochondrial copper relay
system that is required for metallation of COX2. Similar to
SCO2 (Horng et al., 2005), heterologously expressed COA6 pu-
rified from E. coli is copper loaded. While it is tempting to inter-
pret this as evidence that COA6 is an active constituent of the
copper relay system, direct proof that COA6 binds copper within
the mitochondrial intermembrane space is still lacking. It is inter-
esting to note, however, that the interaction between SCO2 and
its substrate COX2 is affected in cells with reduced COA6 levels.
Moreover, we find that the interaction between SCO2 and COA6
is lost in human cells upon treatment with thiamphenicol to block
mitochondrial translation. These observations suggest that
newly synthesized COX2 is required for complex formation be-
tween SCO2 and COA6. In agreement with this, BN-PAGE
analyses indicate that SCO2, COX2, and COA6 form a ternary
complex in human mitochondria. However, the order of events
that lead to the formation of this complex remains unclear. While
the interaction betweenCOA6 and SCOproteins and the interac-
tion of COA6 and COX2 are conserved between yeast and
humans, there are a number of notable differences. Unlike
the human situation, binding of Coa6 to Sco1/2 is enhancedCin the absence of Cox2 in yeast, while a lack of Sco1 promotes
the association between Cox2 and Coa6. Hence, the interac-
tions between Coa6 and Sco1/2 or Cox2 appear to be mutually
exclusive. Since yeast Sco1, the homolog of human SCO1 and
SCO2, is dispensable for Coa6 binding to Cox2, it is conceivable
that human COA6 associates with COX2 prior to SCO2 recruit-
ment into the ternary COX2/COA6/SCO2 complex. In summary,
our observations in the yeast model are in agreement with a sce-
nario in which Coa6 acts in two distinct reaction steps, on the
one hand interacting with Sco1/2 and on the other forming a
complex with newly synthesized Cox2. In humans, these mutu-
ally exclusive interactions have evolved into a ternary complex
formation indicative of a coupled activity that links SCO2 directly
to the COX2 substrate.
We suggest a model in which in human mitochondria COA6
promotes copper transfer to COX2. This process appears to
occur directly on newly synthesized COX2. In yeast, the process
seems to be constituted of independent binding reactions and
to occur in a sequential manner. Our data suggest that one pos-
sibility is that COA6 could transfer copper directly to COX2 after
being loaded with copper by SCO proteins. Alternatively, COA6
may need to be copper-loaded to act as a chaperone tomaintain
the COX2 tail in a competent state for receiving copper ions
from SCO proteins. Reconstitution of this process in vitro will
be required to discriminate between these two mechanistic
possibilities.
EXPERIMENTAL PROCEDURES
Yeast Strains, Handling, and Mitochondrial Preparation
All S. cerevisiae strains used in this study are listed in Table S1. Chromosomal
deletion of COA6 was generated by introduction of the HIS3MX6 cassette
(Knop et al., 1999). Yeast strains were transformed with PCR-amplified inte-
gration-cassettes by the lithium acetatemethod (Ito et al., 1983) and confirmed
by PCR and western blot analysis. In general, yeast cells were grown in liquid
media containing 1% yeast extract, 2% peptone, and 2% galactose at 30C
with shaking (150–220 rpm). Mitochondria were isolated essentially as previ-
ously described (Meisinger et al., 2006). For steady-state analysis ofmitochon-
drial proteins, different amounts were subjected to SDS-PAGE, followed by
western blot analysis.
Cell Culturing, siRNA Constructs, Mutagenesis, and Transfection
Human embryonic kidney cell lines (HEK293T and Flp-InTM T-RExTM 293)
were cultured using DMEM supplemented with 10% (v/v) fetal bovine
serum (GIBCO, Invitrogen), 2 mM L-glutamine, and 50 mg/ml uridine at
37C under a 5% CO2-humidified atmosphere. For inhibition of cytosolic
or mitochondrial translation, DMEM medium was supplemented with
20 mg/ml emetine (Sigma-Aldrich) for 6 hr or with 50 mg/ml thiamphenicol
(Sigma-Aldrich) for 3 days, respectively. Constructs for the inducible
expression of C-terminally FLAG-tagged COA6 and SCO2 were amplified
by PCR using cDNA templates obtained from HEK293 cells. Primers
were designed based on the sequences, Genbank: NM_001012985.2,
NM_005138.2 (COA6 and SCO2, respectively). FLAG peptide sequence
was introduced 50 of the stop codon in the reverse primer. Amplicons
and pcDNA5/FRT/TO (Invitrogen) were digested with appropriate enzymes,
ligated and confirmed by sequencing. Cell lines expressing the transcript of
interest were generated as previously described (Dennerlein et al., 2010).
For COA6 knock-down, siRNA (50-GCUUCAUCGCAGUAGGAAU-30) was
used at 33 nM. Reverse transfections were performed as previously
described (Mick et al., 2012) using approximately 250,000 cells/25 cm2,
lipofectamine RNAiMAX (Invitrogen) and OPTIMEM-I medium. Cells
were harvested and analyzed after 3, 4 and 6 days for growth kinetic exper-
iments and after 4 days for biochemical experiments. Site-directed muta-
genesis was carried out using the Quickchange Lightning Site-Directedell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc. 831
Mutagenesis Kit (Agilent Technologies), according to manufacturer instruc-
tions. To generate COA6 mutants, COA6FLAG was cloned into pCDNA5 and
used as template. For SCO2 mutants, the SCO2HA in pcDNA3.1 was used
as template (SCO2HA was generated by PCR amplification from cDNA using
primers designed based on the sequence, Genbank: NM_005138.2, and HA
was introduced 50 of the stop codon in the reverse primer). Transient trans-
fections were performed according to manufacturer’s instructions using
GeneJuice (Novagen). Briefly, approximately 300,000 cells/25 cm2 were
transfected using 4 mg of transfection reagent and 1 mg of DNA. Cells
were collected 48 hr after transfection.
RT-PCR Analysis
RNA was extracted from various organs of FVB mice. Reverse transcription
was performedwith 2 mg of RNA and a first strand cDNA synthesis kit (Fermen-
tas). Quantification of mRNA levels was performed using 1 ml of cDNA reaction
and SYBR Green qPCR reaction kit (Clontech) and a MX3000P light cycler
(Stratagene). Primers used for quantification: mS12 forward 50-GAAGCTGC
CAAGGCCTTAGA-30, mS12-rev 50-AACTGCAACCAACCACCTTC-3, COA6-
forward 50-CCTTCCATGAAGGAAAGGCA-30, and COA6-rev 50-ACTGGAA
TCCTCCTGCTTCAA-30.
Mitochondrial Isolation from Mammalian Cells and Localization
Analysis
Mitochondria were isolated by differential centrifugation as previously
described (Lazarou et al., 2009). Protein concentration was measured by
Bradford analysis using BSA as a standard. Membrane integration of
proteins was determined by incubation of mitochondria with 100 mM
Na2CO3 (pH 10.8 or 11.5) followed by centrifugation for 30 min at
100,000 3 g at 4C. Submitochondrial localization was analyzed by prote-
ase protection assay (Mick et al., 2012): mitochondrial membranes were
osmotically stabilized in SEM buffer (250 mM sucrose, 1 mM EDTA, and
10 mM MOPS [pH 7.2]), outer mitochondrial membrane ruptured by EM
buffer (1 mM EDTA and 10 mM MOPS [pH 7.2]), or mitochondrial mem-
branes disrupted by sonication in the presence of proteinase K. After incu-
bation for 10 min on ice, reactions were stopped by addition of 1 mM
PMSF.
Labeling of Mitochondrial Translation Products
In vivo labeling in human cells was performed as described previously (Cho-
myn, 1996). Cytosolic translation was inhibited with 100 mg/ml emetine (Invi-
trogen) and mitochondrial translation pulsed with 0.2 mCi/ml [35S]methionine
for 1 hr. In vivo labeling in whole yeast cells was performed essentially as
described (Mick et al., 2010). In brief, yeast cells were resuspended in label-
ing buffer (40 mM potassium phosphate [pH 6.0], 2% galactose). Cyclohex-
imide (150 mg/ml) was used to stop cytoplasmic translation. Samples were
pulse-labeled with 40 mCi [35S]methionine for 10 min at 30C. To analyze
the stability of mitochondrial translation products, mitochondrial translation
was stopped by the addition of chloramphenicol (CAP) and excess methio-
nine. Chase samples were taken after different time points during incubation
at 30C. To visualize radiolabeled proteins, whole-cell extracts were pre-
pared as described above and analyzed by SDS-PAGE and digital autoradi-
ography. For coimmunoprecipitations, translation products were labeled in
isolated yeast mitochondria for 20 min with [35S]methionine at 30C, essen-
tially as described previously (Westermann et al., 2001). After labeling was
stopped by addition of excess methionine, mitochondria were reisolated
and washed with SEM buffer (250 mM saccharose, 1 mM EDTA, and
10 mM MOPS) prior to co-immunoprecipitation.
Miscellaneous
Structure of subunit II of the cytochrome c oxidase (COX2) (PDB: 3ASN)
was modeled using Swiss-PDB viewer and PyMOL Molecular Graphics
System, Version 1.5.0.4 Schro¨dinger, LLC. Standard methods were used
for SDS-PAGE and western blotting of proteins adsorbed to polyvinyli-
dene fluoride membranes (Millipore). Primary antibodies were raised in
rabbit or purchased (anti-SCO1, Abcam; anti-SCO2 and anti-COX2, Pro-
teintech). Antigen-antibody complexes were detected by HRP-coupled
secondary antibodies and enhanced chemiluminescence detection on
X-ray films.832 Cell Metabolism 21, 823–833, June 2, 2015 ª2015 Elsevier Inc.SUPPLEMENTAL INFORMATION
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